Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 6, Pages 687-698Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2017.1323870
Keywords
Schizophrenia; Investigational antipsychotics; Phase II; agonist; antagonist; dopamine
Categories
Funding
- Korean Health Technology R&D Project, Ministry of Health and Welfare [HI12C0003]
Ask authors/readers for more resources
Introduction: Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D-2 receptors.Areas covered: We searched for investigational drugs using the key words dopamine' and schizophrenia' in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library.Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as investigational dopamine antagonists,' just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available